ORIGINAL ARTICLE

Serum Irisin Levels in Cigarette Smokers
Sigara İçenlerde Serum İrisin Düzeyleri
Received Date : 19 Oct 2020
Accepted Date : 31 Dec 2020
Available Online : 09 Mar 2021
Doi: 10.25179/tjem.2020-79650 - Makale Dili: EN
Turk J Endocrinol Metab. 2021;25:95-101
Bu makale, CC BY-NC-SA altında lisanslanmış açık erişim bir makaledir.
ABSTRACT
Objective: Irisin, a newly discovered myokine, increases thermogenesis and energy consumption, especially after exercise. It has also been reported to stimulate the transformation of white fat cells into brown fat cells. Thus, it causes weight loss and increases the sensitivity to insulin. Nicotine affects the energy metabolism of the body through several mechanisms. Cigarette smokers are widely known to show decreased weight gain and increased weight loss. Since irisin and smoking/nicotine have similar effects on energy metabolism, this study proposed to determine the serum irisin levels in smokers. Material and Methods: Thirty-one healthy smokers aged 17-24 years and 31 agematched healthy non-smokers were included in this study. Serum irisin levels were determined using ELISA. Results: The smokers had been smoking for an average of 31±19 (2-84) months and smoked an average of 13.7±0.4 (5-25) cigarettes daily. The smokers had higher height and body weight and levels of serum creatinine and triglyceride and lower levels of HDL-C than non-smokers (p<0.05). Serum irisin levels and body mass index were not different between the two groups (p>0.05). The serum irisin level was correlated only with serum creatinine level in the entire group (r=-0.26, p<0.05). The serum irisin levels were not correlated with the duration and amount of cigarette smoking, as well as levels of serum glucose, insulin, total cholesterol, triglyceride, LDL-C, HDL-C, alanine aminotransferase, free T4, and TSH in the entire group (p>0.05). Conclusion: Serum irisin level in cigarette smokers is not different to that of non-smokers. It is not related to the duration and amount of cigarette smoking. Further prospective dose and time-controlled studies are needed to investigate whether similar effects of smoking/nicotine exposure on energy metabolism are related to irisin metabolism.
ÖZET
Amaç: İrisin, özellikle egzersizden sonra termogenezisi ve enerji harcanmasını artıran yeni tanımlanmış bir miyokindir. Aynı zamanda beyaz yağ dokusu hücrelerine, kahverengi yağ dokusu hücresi özellikleri kazandırdığı rapor edilmiştir. Böylece kilo kaybına neden olur ve insülin duyarlılığının artışına neden olur. Nikotin, pek çok değişik mekanizma ile vücut enerji metabolizmasını etkilemektedir. Sigara içenlerde kilo alımının azaldığı ve kilo kaybının arttığı yaygın olarak bilinmektedir. İrisin ve sigara içiminin/nikotinin enerji metabolizmasında benzer etkileri olduğu görüldüğü için bu çalışmada sigara içenlerde serum irisin düzeylerinin tayini planlanmıştır. Gereç ve Yöntemler: Bu çalışmaya, yaşları 17-24 yıl arasında değişen 31 sağlıklı, sigara içen birey ile yaş açısından benzer 31 sağlıklı, sigara içmeyen birey dâhil edildi. Serum irisin düzeyleri ELISA yöntemi ile tayin edildi. Bulgular: Sigara içenlerde sigara içimi süresi ortalama 31±19 (2-84) ay ve içilen sigara adedi ortalama 13,7±0,4 (5-25) idi. Sigara içen bireylerin boy uzunluğu, vücut ağırlığı, serum kreatinin, trigliserid düzeyleri sigara içmeyenlerden yüksek iken, HDLK düzeyleri daha düşük idi (p<0,05). Sigara içenlerin serum irisin düzeyleri ve beden kitle indeksi, sigara içmeyenlerden farklı değildi (p>0,05). Serum irisin düzeyleri, sadece tüm çalışma grubunda serum kreatinin düzeyleri ile korele idi (r=- 0,26, p<0,05). Serum irisin düzeyleri ile sigara içim süresi, sigara miktarı, serum glukoz, insülin, total kolesterol, trigliserid, LDL-K, HDL-K, alanin transaminaz, serbest T4 ve TSH düzeyleri arasında bir korelasyon saptanmadı (p>0,05). Sonuç: Sigara içenlerde serum irisin düzeyleri, sigara içmeyenlerden farklı değildir. Serum irisin düzeyleri, sigara içiminin süresi ve miktarıyla ilişkili değildir. Sigara içiminin enerji metabolizmasındaki benzer etkilerinin, irisin metabolizmasıyla ilişkili olup olmadığı ileriye dönük, doz ve zaman kontrollü çalışmalarla araştırılmalıdır.
KAYNAKLAR
  1. Bargut TCL, Souza-Mello V, Aguila MB, Mandarim-de-Lacerda CA. Browning of white adipose tissue: lessons from experimental models. Horm Mol Biol Clin Investig. 2017;18;31[Crossref] [PubMed] 
  2. Panati K, Suneetha Y, Narala VR. Irisin/FNDC5--an updated review. Eur Rev Med Pharmacol Sci. 2016;20:689-97.[PubMed] 
  3. Brees DJ, Elwell MR, Tingley FD 3rd, Sands SB, Jakowski AB, Shen AC, Cai JH, Finkelstein MB. Pharmacological effects of nicotine on norepinephrine metabolism in rat brown adipose tissue: relevance to nicotinic therapies for smoking cessation. Toxicol Pathol. 2008;36:568-75.[Crossref] [PubMed] 
  4. Zoli M, Picciotto MR. Nicotinic regulation of energy homeostasis. Nicotine Tob Res. 2012;14:1270-90.[Crossref] [PubMed] [PMC] 
  5. Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA, Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi SP, Spiegelman BM. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature. 2012;11;481:463-8.[Crossref] [PubMed] [PMC] 
  6. Irving BA, Still CD, Argyropoulos G. Does IRISIN Have a BRITE future as a therapeutic agent in humans? Curr Obes Rep. 2014;2;3:235-41.[Crossref] [PubMed] [PMC] 
  7. Leung PS. The potential of irisin as a therapeutic for diabetes. Future Med Chem. 2017;9:529-32.[Crossref] [PubMed] 
  8. Polyzos SA, Anastasilakis AD, Efstathiadou ZA, Makras P, Perakakis N, Kountouras J, Mantzoros CS. Irisin in metabolic diseases. Endocrine. 2018;59:260-74.[Crossref] [PubMed] 
  9. Stengel A, Hofmann T, Goebel-Stengel M, Elbelt U, Kobelt P, Klapp BF. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity--correlation with body mass index. Peptides. 2013;39:125-30.[Crossref] [PubMed] 
  10. Chen H, Vlahos R, Bozinovski S, Jones J, Gary P, Anderson GP, Morris MJ. Effect of short-term cigarette smoke exposure on body weight, appetite and brain neuropeptide Y in mice. Neuropsychopharmacology. 2005;30:713-9.[Crossref] [PubMed] 
  11. Yoshida T, Sakane N, Umekawa T, Kogure A, Kondo M, Kumamoto K, Kawada T, Nagase I, Saito M. Nicotine induces uncoupling protein 1 in white adipose tissue of obese mice. Int J Obes Relat Metab Disord. 1999;23:570-5.[Crossref] [PubMed] 
  12. Arai K, Kim K, Kaneko K, Iketani M, Otagiri A, Yamauchi N, Shibasaki T. Nicotine infusion alters leptin and uncoupling protein 1 mRNA expression in adipose tissues of rats. Am J Physiol Endocrinol Metab. 2001;280:867-76.[Crossref] [PubMed] 
  13. Chiolero A, Faeh D, Paccaud F, Cornuz J. Consequences of smoking for body weight, body fat distribution, and insulin resistance. Am J Clin Nutr. 2008;87:801-9.[Crossref] [PubMed] 
  14. Chiolero A, Jacot-Sadowski I, Faeh D, Paccaud F, Cornuz J. Association of cigarettes smoked daily with obesity in a general adult population. Obesity (Silver Spring). 2007;15:1311-8.[Crossref] [PubMed] 
  15. Klangjareonchai T, Nimitphong H, Saetung S, Bhirommuang N, Samittarucksa R, Chanprasertyothin S, Sudatip R, Ongphiphadhanakul B. Circulating sclerostin and irisin are related and interact with gender to influence adiposity in adults with prediabetes. Int J Endocrinol. 2014;2014:261545.[Crossref] [PubMed] [PMC] 
  16. Anastasilakis AD, Polyzos SA, Saridakis ZG, Kynigopoulos G, Skouvaklidou EC, Molyvas D, Vasiloglou MF, Apostolou A, Karagiozoglou-Lampoudi T, Siopi A, Mougios V, Chatzistavridis P, Panagiotou G, Filippaios A, Delaroudis S, Mantzoros CS. Circulating irisin in healthy, young individuals: day-night rhythm, effects of food intake and exercise, and associations with gender, physical activity, diet, and body composition. J Clin Endocrinol Metab. 2014;99:3247-55.[Crossref] [PubMed] 
  17. Elizondo-Montemayor L, Mendoza-Lara G, Gutierrez-DelBosque G, Peschard-Franco M, Nieblas B, Garcia-Rivas G. Relationship of circulating ırisin with body composition, physical activity, and cardiovascular and metabolic disorders in the pediatric population. Int J Mol Sci. 2018;23;19:3727.[Crossref] [PubMed] [PMC] 
  18. Zügel M, Qiu S, Laszlo R, Bosnyák E, Weigt C, Müller D, Diel P, Steinacker JM, Schumann U. The role of sex, adiposity, and gonadectomy in the regulation of irisin secretion. Endocrine. 2016;54:101-10.[Crossref] [PubMed] [PMC]